Screener
Ultragenyx Pharmaceutical RARE Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The source filing: Ultragenyx Pharmaceutical’s 10-K, filed February 18, 2026.
- Filed
- Feb 18, 2026, 4:59 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-057329
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from the sale of future royalties, net | 392 | — | — |
| Proceeds from the issuance of common stock and pre-funded warrants in connection with underwritten public offerings, net | — | 381 | 326 |
| Proceeds from the issuance of common stock in connection with at-the-market offering, net | 80 | — | 53 |
| Proceeds from the issuance of common stock under equity plans, net | 6 | 11 | 8 |
| Proceeds from issuance of equity from noncontrolling interest | — | 7 | — |
| Other | — | — | 1 |
| Net cash provided by financing activities | 478 | 399 | 388 |
| Effect of exchange rate changes on cash | 4 | (2) | — |
Item 16. Form 10-K Summary
FAQ
- What is Ultragenyx Pharmaceutical's stock issuance proceeds?
- Ultragenyx Pharmaceutical (RARE) reported stock issuance proceeds of $1.5M in Q4 2025.
- How has Ultragenyx Pharmaceutical's stock issuance proceeds changed year-over-year?
- Ultragenyx Pharmaceutical's stock issuance proceeds decreased by 45.5% year-over-year, from $2.75M to $1.5M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Ultragenyx Pharmaceutical's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude